Cowen and Company Reiterates Buy Rating for Stemline Therapeutics, Inc. (STML)

Cowen and Company reissued their buy rating on shares of Stemline Therapeutics, Inc. (NASDAQ:STML) in a report published on Friday, May 12th.

“STML reported 1Q17 financials and provided a pipeline update.”,” the firm’s analyst commented.

STML has been the topic of a number of other reports. HC Wainwright restated a buy rating and issued a $34.00 price target on shares of Stemline Therapeutics in a research note on Tuesday, March 28th. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 18th. Wedbush reiterated an outperform rating and set a $11.00 target price on shares of Stemline Therapeutics in a research report on Friday, March 17th. Ladenburg Thalmann Financial Services reiterated a buy rating on shares of Stemline Therapeutics in a research report on Monday, February 6th. Finally, Jefferies Group LLC set a $16.00 target price on Stemline Therapeutics and gave the stock a buy rating in a research report on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $29.17.

Shares of Stemline Therapeutics (NASDAQ:STML) traded up 7.79% during trading on Friday, hitting $8.30. The stock had a trading volume of 691,218 shares. The stock has a 50-day moving average price of $8.08 and a 200 day moving average price of $9.28. Stemline Therapeutics has a 12 month low of $5.50 and a 12 month high of $14.60. The company’s market cap is $194.02 million.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Equities analysts expect that Stemline Therapeutics will post ($2.27) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/06/17/stemline-therapeutics-inc-stml-earns-buy-rating-from-cowen-and-company-updated-updated-updated.html.

A number of large investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares in the last quarter. AXA acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $3,712,000. Renaissance Technologies LLC raised its stake in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of Stemline Therapeutics during the third quarter worth $2,783,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Stemline Therapeutics during the third quarter worth $3,612,000. 54.72% of the stock is currently owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

What are top analysts saying about Stemline Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit